NAIROBI, KENYA – Today, the Pharmacy and Poisons Board (PPB) convened a strategic partners’ meeting to review the findings of a feasibility study conducted by Penam, focusing on the introduction of mandatory bioequivalence (BE) requirements for locally manufactured products in Kenya. The study was supported by the Bill & Melinda Gates Foundation.

The meeting convened representatives from the National Quality Control Laboratory, Bill & Melinda Gates Foundation, USAID-Management Science for Health, Promoting the Quality of Medicines Plus (PQM+) Program, African Pharmaceutical Network (APN), Kenya Healthcare Federation (KHF), Mission for Essential Drugs and Supplies (MEDS), Analight Laboratories, and USP.

This collaborative initiative highlights Kenya’s dedication to strengthening regulatory standards and ensuring the quality and efficacy of pharmaceutical products through rigorous bioequivalence assessments, thereby protecting public health and enhancing local pharmaceutical manufacturing capabilities.